Opipramol API Manufacturers

compare suppliers & get competitive offers

teaser-1024x654-1
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Opipramol is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Opipramol or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Opipramol API 315-72-0?

Description:
Here you will find a list of producers, manufacturers and distributors of Opipramol. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Opipramol 
Synonyms:
 
Cas Number:
315-72-0 
DrugBank number:
DB12930 
Unique Ingredient Identifier:
D23ZXO613C

General Description:

Opipramol, identified by CAS number 315-72-0, is a notable compound with significant therapeutic applications. Opipramol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders.

Classification:

Opipramol belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom, classified under the direct parent group Dibenzazepines. This compound is a part of the Organic compounds, falling under the Organoheterocyclic compounds superclass, and categorized within the Benzazepines class, specifically within the Dibenzazepines subclass.

Categories:

Opipramol is categorized under the following therapeutic classes: Adrenergic Agents, Agents that produce hypertension, Agents that reduce seizure threshold, Antidepressive Agents, Antidepressive Agents, Tricyclic, Central Nervous System Agents, Central Nervous System Depressants, Dibenzazepines, Heterocyclic Compounds, Fused-Ring, Membrane Transport Modulators, Narrow Therapeutic Index Drugs, Nervous System, Neurotoxic agents, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Non-Selective Monoamine Reuptake Inhibitors, Psychoanaleptics, Psychotropic Drugs, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Opipramol is a type of Antidepressants


Antidepressants are a category of pharmaceutical Active Pharmaceutical Ingredients (APIs) widely used in the treatment of depression and other mood disorders. These medications work by balancing the levels of certain chemicals in the brain called neurotransmitters, such as serotonin, norepinephrine, and dopamine.

There are several types of antidepressants available, each with its own mechanism of action and efficacy. Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed as a first-line treatment for depression. They prevent the reabsorption of serotonin, resulting in increased serotonin levels in the brain. Examples of popular SSRIs include fluoxetine, sertraline, and escitalopram.

Tricyclic antidepressants (TCAs) are another class of antidepressants that work by blocking the reuptake of both serotonin and norepinephrine. They are generally used when SSRIs are ineffective or not well-tolerated. Amitriptyline, nortriptyline, and imipramine are commonly prescribed TCAs.

Other antidepressants include serotonin-norepinephrine reuptake inhibitors (SNRIs), atypical antidepressants, and monoamine oxidase inhibitors (MAOIs). SNRIs, such as venlafaxine and duloxetine, inhibit the reuptake of both serotonin and norepinephrine. Atypical antidepressants, including bupropion and mirtazapine, have diverse mechanisms of action, targeting multiple neurotransmitters. MAOIs, such as phenelzine and tranylcypromine, work by inhibiting the enzyme monoamine oxidase, which breaks down neurotransmitters.

It is important to note that antidepressants may have various side effects and require close monitoring by healthcare professionals. Dosages and treatment duration vary based on individual needs and response. Antidepressants are typically prescribed as part of a comprehensive treatment plan that may include psychotherapy and lifestyle modifications.

In conclusion, antidepressants are a vital category of pharmaceutical APIs used to manage depression and related mood disorders. They act on neurotransmitters in the brain to alleviate symptoms and improve overall well-being. It is crucial to consult with a healthcare provider to determine the most suitable antidepressant and monitor its effects.